The Effects of False Claims Act Whistleblowers on the Pharmaceutical Industry

The Effects of False Claims Act Whistleblowers on the Pharmaceutical Industry

DSpace/Manakin Repository

The Effects of False Claims Act Whistleblowers on the Pharmaceutical Industry

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Davis, Mark S.	en_US
dc.date.accessioned	2012-07-06T21:37:46Z
dc.date.issued	2006	en_US
dc.identifier.citation	The Effects of False Claims Act Whistleblowers on the Pharmaceutical Industry (2006 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965590
dc.description.abstract	The whistleblower (or â€&oelig;qui tamâ€) provisions of the False Claims Act allow private citizens to bring suit on behalf of the government against individuals or corporations who have submitted false or fraudulent claims to the government. Under the Act, a whistleblower is entitled to a percentage of the damages or settlement that the government ultimately receives as a result of the lawsuit. The qui tam provisions have been used with increasing frequency in recent years to initiate lawsuits against pharmaceutical manufacturers for fraud that these companies have allegedly committed against federal and state health care programs. This paper attempts to explain the effects that these whistleblower lawsuits have had upon the pharmaceutical industry. This paper also proposes ways that the False Claims Act and government enforcement efforts could be reformed in order to reduce both frivolous qui tam lawsuits and the need for such extensive False Claims Act prosecution.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	whistle blowers	en
dc.title	The Effects of False Claims Act Whistleblowers on the Pharmaceutical Industry	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-07-06T21:37:46Z